meibomian gland dysfunction
Conditions
Interventions
treatment group:IRPL treatment
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged greater than or equal to 18 years old male and female; 2. The subject signed the informed consent; 3. Main complaint eye dry, eye astringent, visual fatigue and other eye symptoms; 4. Diagnosis of MGD; 5. SPEED score is greater than or equal to 6 points; 6. MGYSS is less than or equal to 12 points; 7. Skin type meets the standard.
Exclusion criteria
Exclusion criteria: 1. Patients with discomfort or adverse reactions to the treatment; 2. 6 months with ocular trauma history and surgical history; 3. Patients with eye inflammation, allergies and other eye diseases; 4. Patients with abnormal eyelids; 5. Within 5.3 months, contact lens wear history; 6. A history of tanning and sunburn within 6.4 weeks; 7. Effects of systemic disease on the eyes or medications that affect the eye table; 8. Patients with lacrimal duct or lacrimal embolism; 9. Treatment area has skin disease or abnormality; 10. The overall condition was poor, and the researchers considered that it was impossible to evaluate the efficacy or to complete the expected course of treatment and follow-up; 11. Disuse eye drops or other treatments other than artificial tears for the first two weeks; 12. Pregnant and lactating women; 13. The clinical researchers judged that the other patients should not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lipid layer thickness;tear break up time;tear inflammatory factor; | — |
Countries
China
Contacts
Public ContactShaozhen Zhao
Tianjin Medical University Eye Hospital
Outcome results
None listed